PBLA
$3.55
Panbela Therapeutics
$.11
3.20%
PBLA
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Wednesday
Aug 11
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when PBLA reports earnings?
Beat
Meet
Miss

Where is PBLA's stock price going from here?
Up
Flat
Down
Stock chart of PBLA
Analysts
Summary of analysts' recommendations for PBLA
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Panbela Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics Inc., formerly known as Sun BioPharma Inc., is based in MINNEAPOLIS.